ABVC BioPharma, Inc. ABVC 深 沪
等待开盘 05-20 09:30:00 美东时间
1.10
+0.030
+2.80%
华盛通- 最 高1.11
- 今 开1.09
- 成交量 6.67万股
- 最 低 1.015
- 昨 收 1.07
- 总市值 2820.09万
- 52周最高 5.48
- 市盈率 静 --
- 换手率 0.26%
- 52周最低 0.8801
- 委 比 95.27%
- 总股本 2563.72万
- 历史最高 116.90
- 量 比 0.74
- 振 幅 8.88%
- 历史最低 0.40
- 每 手 1
- 风险率 0.79%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多ABVC BioPharma Q1 EPS $(0.06), Same YoY
ABVC BioPharma (NASDAQ:ABVC) reported quarterly losses of $(0.06) per share. This is unchanged from the same period last year.
05-18 21:26
Why Silo Pharma Shares Are Trading Higher By Around 52%; Here Are 20 Stocks Moving Premarket
SILO stock rose 51.8% in pre-market trading after its PTSD treatment pipeline received a patent from the European Patent Office targeting 5-HT4.
04-07 17:20
美股夜盘 | Mawson Infrastructure Group Inc涨40.15%，Organogenesis Holdings, Inc. Class A涨29.46%
Mawson Infrastructure Group Inc涨40.15%；Organogenesis Holdings, Inc. Class A涨29.46%；Alignment Healthcare, Inc.涨15.85%
04-07 15:01
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Profusa (NASDAQ:PFSA) shares rose 148.0% to $1.88 during Monday's regul...
04-07 01:05
ABVC BioPharma Q3 EPS $(0.05) Down From $(0.03) YoY, Sales $795.950K Up From $389.276K YoY
ABVC BioPharma (NASDAQ:ABVC) reported quarterly losses of $(0.05) per share. This is a 66.67 percent decrease over losses of $(0.03) per share from the same period last year. The company reported $795.950 thousand in
2025-11-03 22:16
ABVC BioPharma Q2 EPS $(0.13) Down From $(0.09) YoY
ABVC BioPharma (NASDAQ:ABVC) reported quarterly losses of $(0.13) per share. This is a 44.44 percent decrease over losses of $(0.09) per share from the same period last year.
2025-08-14 05:40
快讯 | ABVC生物制药公司申请混合货架，最高达1亿美元 - SEC文件
ABVC Biopharma Inc Files for Mixed Shelf of up to $100 Mln - SEC Filing
2025-05-23 04:02
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Biodesix (NASDAQ:BDSX) shares increased by 72.6% to $0.47 during Wedne...
2025-05-22 01:06
'ABVC BioPharma Secures Japanese Patent For Its Natural MDD Treatment Candidate ABV-1504'
ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical-stage biopharmaceutical company developing botanical-based therapies for central nervous system (CNS), ophthalmology, and oncology/hematology indications, today announced
2025-05-09 23:05
